#USA #New York #Securities Fraud #Rosen Law Firm #ADMA Biologics

Important Deadlines for ADMA Investors

A crucial reminder has been issued by the Rosen Law Firm, a renowned global advocate for investor rights. They announce that those who purchased securities of ADMA Biologics, Inc. (NASDAQ: ADMA) during the class period spanning from August 9, 2024, to March 25, 2026, have a significant opportunity to seek legal recourse. This period of time marks the alleged violations for which the company may face legal repercussions.

Class Action Overview

Those affected have until August 10, 2026, to apply to be the lead plaintiff in this securities class action lawsuit recently filed by the Rosen Law Firm. A lead plaintiff serves as a key figure representing the collective interests of all involved investors and directing the course of the litigation. This representation is particularly significant in a case as complex as this, ensuring that the collective rights of the investors are protected effectively.

Your Rights and Actions

If you have held ADMA securities within the stipulated timespan, you might be eligible for compensation without needing to pay out-of-pocket expenses. The Rosen Law Firm operates on a contingency fee basis, ensuring that no upfront costs are incurred by those involved. Potential plaintiffs need only to visit the law firm's website or contact them directly for more detailed information regarding participation in this lawsuit.

The Basis of the Lawsuit

The lawsuit alleges that ADMA Biologics engaged in numerous deceptive practices, including failing to disclose vital information concerning the company's operations. Such activities have purportedly resulted in significant financial losses for investors once the truth became public. The key allegations include:

• - Involvement in undisclosed related-party transactions.
• - Use of channel stuffing tactics, which are practices used to artificially inflate revenues by shipping more products to retailers than they can sell.
• - A lack of adequate internal controls.
• - Overall misleading statements regarding the company's health and prospects.

Such practices have led to a lack of trust and credibility in ADMA Biologics, culminating in severe damages reported by investors once the misinformation was revealed.

Importance of Qualified Representation

Rosen Law Firm urges affected investors to seek representation from qualified counsel who have a proven record in securities class action cases. Many firms that advertise these proceedings might not possess the necessary experience, which could jeopardize the outcome of the litigation.

The Rosen Law Firm prides itself on its successful background, having achieved significant settlements on behalf of its clients, including the largest-ever securities class action settlement against a Chinese company. In 2019 alone, they secured over $438 million for investors, underscoring the firm's effectiveness in navigating complex securities litigation.

How to Join the Class Action

For investors interested in joining or learning more about the ongoing lawsuit against ADMA Biologics, you can visit the Rosen Law Firm’s dedicated web page for ADMA cases at Rosen Legal or reach out to Phillip Kim, Esq., toll-free at 866-767-3653. Alternatively, individuals can also email [email protected] to receive guidance on how to proceed.

This lawsuit is still in its early stages, and as such, no class has been certified, meaning that investors are not automatically represented unless they actively choose to join and retain counsel. It's important to act quickly due to the approaching lead plaintiff deadline to ensure your rights are secured.

Stay informed as developments unfold. Follow Rosen Law Firm on platforms like LinkedIn and Twitter for timely updates on this and other legal matters pertaining to securities and investor rights.